Impact of different classes of antidepressants on sleep and wakefulness regulation in depression
https://doi.org/10.14412/2074-2711-2022-1-82-88
Abstract
Sleep disturbances are common in patients with mental disorders. Sleep disturbances, in particular insomnia, are widespread in depression. Depressed patients have a lot of sleep complaints that are often confirmed by polysomnography. Most antidepressants impair sleep, so drugs that help to restore sleep are of particular value in clinical practice. Agomelatine (valdoxan) rapidly improves sleep in depressed patients by making it easier to fall asleep, increasing total sleep time, duration of rapid eye movement (REM), and slow-wave sleep (SWS), and improving functioning during the day.
About the Authors
G. M. Usov
Omsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
12, Lenin St., Omsk 644099
D. Yu. Kolomytsev
Omsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
12, Lenin St., Omsk 644099
L. M. Lomiashvili
Omsk State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
12, Lenin St., Omsk 644099
References
1. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). doi: 10.1176/appi.books.9780890425596
2. Dmitrieva TB, Holland VB, Kazakovtseva BA, editors. Psikhicheskiye rasstroystva i rasstroystva povedeniya (F00-F99). Klass V MKB-10, adaptirovannyy dlya ispol'zovaniya v RF [Mental and behavioral disorders (F00-F99). Class V ICD-10, adapted for use in the Russian Federation]. Moscow: RIO GNTs SSP im. V.P. Serbskiy; 1998. 360 p. (In Russ.).
3. Wilson S, Nutt D. (2013-09). Sleep Disorders (Oxford Psychiatry Library). Oxford, UK: Oxford University Press; 2013. Available from: https://oxfordmedicine.com/view/10.1093/med/9780199674558.001.0001/med-9780199674558 (accessed 26.07.2021).
4. Poluektov MG. Sleep disorders in psychiatric practice. Sovremennaya terapiya psikhicheskikh rasstroystv. 2012;(4):11-6 (In Russ.).
5. Golenkov AV. Sleep disorders in mental disorders. effective pharmacotherapy. Nevrologiya i psikhiatriya. Spetsvypusk “Son i yego rasstroystva”. 2014;(2):22-9 (In Russ.).
6. Soehner AM, Kaplan KA, Harvey AG. Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. J Affect Disord. 2014;167:93-7. doi: 10.1016/j.jad.2014.05.060. Epub 2014 Jun 6.
7. Takaesu Y. Circadian rhythm in bipolar disorder: A review of the literature. Psychiatry Clin Neurosci. 2018 Sep;72(9):673-82. doi: 10.1111/pcn.12688. Epub 2018 Jul 4.
8. Hensch T, Wozniak D, Spada J, et al. Vulnerability to bipolar disorder is linked to sleep and sleepiness. Transl Psychiatry. 2019 Nov 11;9(1):294. doi: 10.1038/s41398-019-0632-1
9. Cipriani G, Lucetti C, Danti S, et al. Sleep disturbances and dementia. Psychogeriatrics. 2015 Mar;15(1):65-74. doi: 10.1111/psyg.12069. Epub 2014 Dec 16.
10. Wennberg AMV, Wu MN, Rosenberg PB, et al. Sleep Disturbance, Cognitive Decline, and Dementia: A Review. Semin Neurol. 2017 Aug;37(4):395-406. doi: 10.1055/s-0037-1604351. Epub 2017 Aug 24.
11. Cosgrave J, Wulff K, Gehrman P. Sleep, circadian rhythms, and schizophrenia: where we are and where we need to go. Curr Opin Psychiatry. 2018 May;31(3):176-82. doi: 10.1097/YCO.0000000000000419
12. Ferrarelli F. Sleep disturbances in schizophrenia and psychosis. Schizophr Res. 2020 Jul;221:1-3. doi: 10.1016/j.schres.2020.05.022. Epub 2020 May 26.
13. Li P, Gao L, Gaba A, et al. Circadian disturbances in Alzheimer's disease progression: a prospective observational cohort study of community-based older adults. Lancet Healthy Longev. 2020 Dec;1(3):e96-e105. doi: 10.1016/s2666-7568(20)30015-5. Epub 2020 Nov 12.
14. Levin YaI. Depression and sleep. Psikhiatriya i psikhofarmakoterapiya. 2000;2(1):20-3 (In Russ.).
15. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand Suppl. 2007;(433):104-15. doi: 10.1111/j.1600-0447.2007.00968.x
16. Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019 Apr;23(4):2324-32. doi: 10.1111/jcmm.14170. Epub 2019 Feb 7.
17. Lacruz ME, Schmidt-Pokrzywniak A, Dragano N, et al. Depressive symptoms, life satisfaction and prevalence of sleep disturbances in the general population of Germany: results from the Heinz Nixdorf Recall study. BMJ Open. 2016 Jan 4;6(1):e007919. doi: 10.1136/bmjopen-2015-007919
18. Pandi-Perumal SR, Monti JM, Burman D, et al. Clarifying the role of sleep in depression: A narrative review. Psychiatry Res. 2020 Sep;291:113239. doi: 10.1016/j.psychres.2020.113239. Epub 2020 Jun 16.
19. Hawkins DR, Taub JM, van de Castle RL. Extended sleep (hypersomnia) in young depressed patients. Am J Psychiatry. 1985 Aug;142(8):905-10. doi: 10.1176/ajp.142.8.905
20. Lopez R, Barateau L, Evangelista E, Dauvilliers Y. Depression and Hypersomnia: A Complex Association. Sleep Med Clin. 2017 Sep;12(3):395-405. doi: 10.1016/j.jsmc.2017.03.016. Epub 2017 May 26.
21. Lojko D, Rybakowski JK. Atypical depression: current perspectives. Neuropsychiatr Dis Treat. 2017 Sep 20;13:2447-56. doi: 10.2147/NDT.S147317. eCollection 2017.
22. Grigolon RB, Trevizol AP, Cerqueira RO, et al. Hypersomnia and Bipolar Disorder: A systematic review and meta-analysis of proportion. J Affect Disord. 2019 Mar 1;246:659-66. doi: 10.1016/j.jad.2018.12.030. Epub 2018 Dec 18.
23. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues Clin Neurosci. 2008;10(4):473-81. doi: 10.31887/DCNS.2008.10.4/plfranzen
24. Murphy MJ, Peterson MJ. Sleep Disturbances in Depression. Sleep Med Clin. 2015 Mar;10(1):17-23. doi: 10.1016/j.jsmc.2014.11.009. Epub 2014 Dec 12.
25. Steiger A, Pawlowski M, Kimura M. Sleep electroencephalography as a biomarker in depression. Chrono Physiol Ther. 2015;5:15- 25 doi: 10.2147/CPT.S41760
26. Kupfer DJ. The application of EEG sleep in the treatment of depression. In: Mendlewicz J, van Praag HM, editors. Advances in Biological Psychiatry. Basel, Switzerland: S. Karger; 1981. P. 87-93.
27. Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications. 4th ed. Cambridge University Press; 2013.
28. Stahl SM. Stahl's essential psychopharmacology: Prescriber's guide. 5th ed. Cambridge University Press; 2014.
29. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927-47. doi: 10.2165/00003495-200565070-00003
30. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005 Dec;20(8):533-59. doi: 10.1002/hup.726
31. Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017 Aug 9;19(9):63. doi: 10.1007/s11920-017-0816-4
32. Mosolov SN. Trevozhnyye i depressivnyye rasstroystva: komorbidnost' i terapiya [Anxiety and depressive disorders: comorbidity and therapy]. Moscow: Artinfopublishing; 2007. P. 29- 30 (In Russ.).
33. Hartter S, Wang X, Weigmann H, et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol. 2001 Apr;21(2):167-74. doi: 10.1097/00004714-200104000-00008
34. Baldwin DS, et al. Poster presented at the 13th International Forum on Mood and Anxiety Disorders (IFMAD), November 20-22, 2013. Monaco; 2013.
35. Sunami E, Usuda K, Nishiyama Y, et al. A Preliminary Study of Fluvoxamine Maleate on Depressive State and Serum Melatonin Levels in Patients after Cerebral Infarction. Intern Med. 2012;51(10):1187-93. doi: 10.2169/internalmedicine.51.6699. Epub 2012 May 15.
36. Smulevich AB, Ilyina NA, Chitlova VV. Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label Uncontrolled and Randomized Multicenter Observational Study. Psihiatriya i psihofarmakoterapiya. 2016;18(1):4-10 (In Russ.).
37. Hao Y, Hu Y, Wang H, et al. The Effect of Fluvoxamine on Sleep Architecture of Depressed Patients with Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study. Nat Sci Sleep. 2019 Nov 4;11:291-300. doi: 10.2147/NSS.S220947. eCollection 2019.
38. Volel BA. Valdoxan (agomelatine): an innovative mechanism of action. Psihiatriya i psihofarmakoterapiya. 2008;10(3):35-9 (In Russ.).
39. Ivanov SV. Agomelatine (Valdoxan) is the first melatonergic antidepressant. In: Mosolov SN, editor. Khronobiologicheskaya teoriya affektivnykh rasstroystv [Chronobiological theory of affective disorders]. Moscow: AVANPORT; 2014. P. 218-65 (In Russ.).
40. Medvedev V, Retyunskiy KYu, Ovchinnikov AA, et al. The differences in the estimation of depression severity by psychiatrists and patients during the combined treatment with agomelatine (a multicenter study “EMOTSIA”). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(11):26-34. doi: 10.17116/jnevro201611611126-34 (In Russ.).
41. Medvedev V, Retyunskii K, Ovchinnikov A, et al. Differences in Assessment of the Severity of Depression by Doctors and Patients during Combined Therapy with Agomelatine (the EMOTION multicenter trial). Neurosci Behav Physiol. 2018;48:367-76. doi: 10.1007/s11055-018-0572-x
42. Quera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007 Oct;10(5):691-6. doi: 10.1017/S1461145707007754. Epub 2007 May 4.
43. Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi: 10.1097/YIC.0b013e328349b117
44. Ivanov SV. Valdoxan (agomelatine) in the treatment of moderate and severe non-psychotic depression in outpatient and hospital practice (results of the Russian multicenter study “CHRONOS”). Psihiatriya i psihofarmakoterapiya. 2009;11(6):14-7 (In Russ.).
45. Smulevich AB, Andryushchenko AV, Beskova DA. Treatment of non-psychotic depression with the antidepressant agomelatine (Valdoxan): results of the RITM observational multicenter study. Psihiatriya i psihofarmakoterapiya. 2010;12(4):4-11 (In Russ.).
46. Poluektov MG, Levin YaI. The results of the Russian multicenter open observational non-comparative study on the efficacy and safety of valdoxan (agomelatin) in the treatment of patients with major depressive disorder and insomnia (the VIVALDI study). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2013;113(12):39-44 (In Russ.).
Review
For citations:
Usov G.M., Kolomytsev D.Yu., Lomiashvili L.M. Impact of different classes of antidepressants on sleep and wakefulness regulation in depression. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):82-88. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-82-88
Views: 360
Email this article 